HomeAbout

TL;DR CNBC


Novo Nordisk says high-dose experimental obesity pill leads to 15% weight loss - TL;DR CNBC

Novo Nordisk says high-dose experimental obesity pill leads to 15% weight loss

Publishing timestamp: 2023-06-26 13:33:54


Summary

Novo Nordisk's high-dose experimental obesity pill showed promising results in a late-stage clinical trial, helping overweight or obese adults lose around 15% of their body weight. The company plans to file for FDA approval later this year, as it competes with new players like Pfizer and Eli Lilly in the weight loss drug market. The pill is an oral version of semaglutide, the active ingredient in Novo Nordisk's successful injections Ozempic and Wegovy. Other companies are also developing oral weight loss treatments to cater to those who prefer not to have weekly injections.


Sentiment: POSITIVE

Tickers: LLYNOVO.B-DKPFE

Keywords: business newspfizer incbreaking newsfdaweight managementbiotechnologyobesitylilly drnhealth care industrybiotech and pharmaceuticalsnovo nordisk a/ssciencebusinesspharmaceuticalsdiabetes

Source: https://www.cnbc.com/2023/06/26/novo-nordisk-says-high-dose-obesity-pill-leads-to-15percent-weight-loss.html


Developed by Leo Phan